Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12

Cited by (970)

Items 301–400 of 970

1. Microbial metabolites affect tumor progression, immunity and therapy prediction by reshaping the tumor microenvironment (Review)
   Yuhang Zhou, Wenjie Han, Yun Feng, Yue Wang, Tao Sun, Junnan Xu · 2024 · International Journal of Oncology
2. Tumor-specific delivery of clickable inhibitor for PD-L1 degradation and mitigating resistance of radioimmunotherapy
   Bo Hou, Jiayi Ye, Lujia Huang, Wenhao Cheng, Fangmin Chen, Huiling Zhou, Jiaxing Pan, Jing Gao, Yi Lai, Yujun Zhao et al. · 2024 · Science Advances
3. Arginase-1-specific T cells target and modulate tumor-associated macrophages
   Evelina Martinenaite, Inés Lecoq, Mia Aaboe Jørgensen, Shamaila Munir Ahmad, Maria Perez-Penco, Hannah Jorinde Glöckner, Marion Chapellier, Lucía Lara de la Torre, Lars Rønn Olsen, Anne Mette Askehøj Rømer et al. · 2025 · Journal for ImmunoTherapy of Cancer
4. Identification of hub genes in hepatocellular carcinoma using integrated bioinformatic analysis
   Shengni Hua, Zhonghua Ji, Yingyao Quan, Meixiao Zhan, Hao Wang, Wei Li, Yong Li, Xu He, Ligong Lu · 2020 · Aging
5. Inflammasomes in dendritic cells: Friend or foe?
   Lukas Hatscher, Lukas Amon, Lukas Heger, Diana Dudziak · 2021 · Immunology Letters
6. Functional nanovesicles displaying anti-PD-L1 antibodies for programmed photoimmunotherapy
   Hu Chen, Pengfei Zhang, Yesi Shi, Chao Liu, Qianqian Zhou, Yun Zeng, Hongwei Cheng, Qixuan Dai, Xing Gao, Xiaoyong Wang et al. · 2022 · Journal of Nanobiotechnology
7. MHC-II Signature Correlates With Anti-Tumor Immunity and Predicts anti-PD-L1 Response of Bladder Cancer
   Yi, Ruibin, Hong, Shuo, Zhang, Yueming, Lin, Anqi, Ying, Haoxuan, Zou, Weidong, Wang, Qiongyao, Wei, Ting, Cheng, Quan, Zhu, Weiliang et al. · 2022 · Frontiers in Cell and Developmental Biology
8. Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients
   Macandog, Angeli D.G., Catozzi, Carlotta, Capone, Mariaelena, Nabinejad, Amir, Nanaware, Padma P., Liu, Shujing, Vinjamuri, Smita, Stunnenberg, Johanna A., Galiè, Serena, Jodice, Maria Giovanna et al. · 2024 · Cell Host & Microbe
9. Extracellular vesicles at the crossroad between cancer progression and immunotherapy: focus on dendritic cells
   Tiziana Schioppa, Carolina Gaudenzi, Giovanni Zucchi, Arianna Piserà, Yasmin Vahidi, Laura Tiberio, Silvano Sozzani, Annalisa Del Prete, Daniela Bosisio, Valentina Salvi · 2024 · Journal of Translational Medicine
10. Proximity-dependent labeling identifies dendritic cells that drive the tumor-specific CD4 + T cell response
    Aleksey Chudnovskiy, Tiago B. R. Castro, Sandra Nakandakari-Higa, Ang Cui, Chia‐Hao Lin, Moshe Sade-Feldman, Brooke K. Phillips, Juhee Pae, Luka Mesin, Juliana Bortolatto et al. · 2024 · Science Immunology
11. Prediction of hepatocellular carcinoma prognosis based on expression of an immune-related gene set
    Yuting He, Qin Dang, Jie Li, Qiyao Zhang, Xiao Yu, Miaomiao Xue, Wenzhi Guo · 2020 · Aging
12. Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches
    Ji‐Yoon Noh, Huiyun Seo, Jungwoon Lee, Haiyoung Jung · 2020 · International Journal of Molecular Sciences
13. Revolutionizing cancer treatment: The power of dendritic cell-based vaccines in immunotherapy
    Mohsen Sheykhhasan, Amirhossein Ahmadieh-Yazdi, Reza Heidari, Mohsen Chamanara, Mohammad Akbari, Naresh Poondla, Piao Yang, Sara Malih, Hamed Manoochehri, Hamid Tanzadehpanah et al. · 2025 · Biomedicine & Pharmacotherapy
14. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance
    Yaqi Li, Jing Liu, Long Gao, Yuan Liu, Fang Meng, Xiaoan Li, Frank Xiao-Feng Qin · 2019 · Immunology Letters
15. Molecular Imaging for Cancer Immunotherapy: Seeing Is Believing
    Madiha Saeed, Zhiai Xu, Bruno G. De Geest, Huixiong Xu, Haijun Yu · 2020 · Bioconjugate Chemistry
16. Tumor-specific T cells support chemokine-driven spatial organization of intratumoral immune microaggregates needed for long survival
    Ziena Abdulrahman, Saskia J A M Santegoets, Gregor Sturm, Pornpimol Charoentong, Marieke E. Ijsselsteijn, Antonios Somarakis, Thomas Höllt, Francesca Finotello, Zlatko Trajanoski, Sylvia L. van Egmond et al. · 2022 · Journal for ImmunoTherapy of Cancer
17. Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy
    Álvaro Teijeira, Saray Garasa, Carlos Luri‐Rey, Carlos de Andrea, María Gato, Carmen Molina, Tsuneyasu Kaisho, Assunta Cirella, Arantza Azpilikueta, Stefanie K. Wculek et al. · 2022 · Cancer Research
18. TGF-β orchestrates the phenotype and function of monocytic myeloid-derived suppressor cells in colorectal cancer
    Luciana Gneo, Nagy Rizkalla, Rahul K. Hejmadi, Francis Mussai, Carmela De Santo, Gary Middleton · 2021 · Cancer Immunology Immunotherapy
19. Spatial determinants of CD8+ T cell differentiation in cancer
    Katherine Tooley, Giulia Escobar, Ana Carrizosa Anderson · 2022 · Trends in cancer
20. Multifunctional nanoparticles precisely reprogram the tumor microenvironment and potentiate antitumor immunotherapy after near-infrared-II light-mediated photothermal therapy
    Yanni Ge, Jiaojiao Zhang, Kai Jin, Ziqiang Ye, Wei Wang, Zhuxian Zhou, Juan Ye · 2023 · Acta Biomaterialia
21. The spread of interferon-γ in melanomas is highly spatially confined, driving nongenetic variability in tumor cells
    Edoardo Centofanti, Chad Wang, Sandhya Iyer, Oleg Krichevsky, Alon Oyler‐Yaniv, Jennifer E. Oyler · 2023 · Proceedings of the National Academy of Sciences
22. Notch-Regulated Dendritic Cells Restrain Inflammation-Associated Colorectal Carcinogenesis
    Lei Wang, Shuiliang Yu, Ernest Ricky Chan, Kai-Yuan Chen, Cui Liu, Danian Che, Amad Awadallah, Jay Myers, David Askew, Alex Yee-Chen Huang et al. · 2021 · Cancer Immunology Research
23. Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma
    Alex Chehrazi‐Raffle, Luis Alfredo Meza, Marice B. Alcantara, Nazlı Dizman, Paulo Gustavo Bergerot, Nicholas Salgia, Joann Hsu, Nora H. Ruel, Sabrina K. Salgia, Jasnoor Malhotra et al. · 2021 · Journal for ImmunoTherapy of Cancer
24. The Current Application and Future Prospects of Astragalus Polysaccharide Combined With Cancer Immunotherapy: A Review
    Fanming Kong, Tianqi Chen, Xiaojiang Li, Yingjie Jia · 2021 · Frontiers in Pharmacology
25. Intratumoral administration of CD1c (BDCA-1) + and CD141 (BDCA-3) + myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial
    Julia Katharina Schwarze, Jens Tijtgat, Gil Awada, Louise Cras, Angela Vasaturo, Christopher J. Bagnall, Ramses G. Forsyth, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet et al. · 2022 · Journal for ImmunoTherapy of Cancer
26. Boosting Interleukin‐12 Antitumor Activity and Synergism with Immunotherapy by Targeted Delivery with isoDGR‐Tagged Nanogold
    Gasparri, Anna Maria, Sacchi, Angelina, Basso, Veronica, Cortesi, Filippo, Freschi, Massimo, Rrapaj, Eltjona, Bellone, Matteo, Casorati, Giulia, Dellabona, Paolo, Mondino, Anna et al. · 2019 · Small
27. Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade
    Cassia Wang, Lee Chen, Doris Fu, Wendi Liu, Anusha Puri, M Kellis, Jiekun Yang · 2024 · Clinical & Experimental Metastasis
28. Anti-PD-1 cis-delivery of low-affinity IL-12 activates intratumoral CD8+T cells for systemic antitumor responses
    Zhuangzhi Zou, Jiao Shen, Diyuan Xue, Hongjia Li, Longxin Xu, Weian Cao, Wenyan Wang, Yang‐Xin Fu, Hua Peng · 2024 · Nature Communications
29. YTHDF2: a key RNA reader and antitumor target
    Sai Jin Xiao, Songqi Duan, Michael A. Caligiuri, Shoubao Ma, Jianhua Yu · 2025 · Trends in Immunology
30. Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer
    Colt A. Egelston, Weihua Guo, Susan Elaine Yost, Jin Sun Lee, David L. Rose, Christian Avalos, Jian Ye, Paul Henry Frankel, Daniel D. Schmolze, James Ross Waisman et al. · 2021 · Journal for ImmunoTherapy of Cancer
31. Spatial Deconvolution of HER2-positive Breast Tumors Reveals Novel Intercellular Relationships
    Alma Andersson, Ludvig Larsson, Linnea Stenbeck, Fredrik Salmén, Anna Ehinger, Sunny Z. Wu, Ghamdan Al‐Eryani, Daniel Lee Roden, Alexander Swarbrick, Åke Borg et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
32. Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma
    Xin Liu, Hui Shen, Lu Zhang, Wenhui Huang, Shuixing Zhang, Bin Zhang · 2024 · npj Precision Oncology
33. Screening for new macrophage therapeutics
    Christopher B. Rodell, Peter David Koch, Ralph Weissleder · 2019 · Theranostics
34. Simultaneous targeting of primary tumor, draining lymph node, and distant metastases through high endothelial venule-targeted delivery
    Liwei Jiang, Sungwook Jung, Jing Zhao, Vivek Kasinath, Takaharu Ichimura, John Joseph, Paolo Fiorina, Andrew Scott Liss, Khalid Shah, Nasim Annabi et al. · 2020 · Nano Today
35. Combining an Alarmin HMGN1 Peptide with PD-L1 Blockade Results in Robust Antitumor Effects with a Concomitant Increase of Stem-Like/Progenitor Exhausted CD8+ T Cells
    Chang-Yu Chen, Satoshi Ueha, Yoshiro Ishiwata, Shigeyuki Shichino, Shoji Yokochi, De Yang, Joost J. Oppenheim, Haru Ogiwara, Shungo Deshimaru, Yuzuka Kanno et al. · 2021 · Cancer Immunology Research
36. RNA N6‐methyladenosine modification in the lethal teamwork of cancer stem cells and the tumor immune microenvironment: Current landscape and therapeutic potential
    Zhihui Zhang, Chaoqi Zhang, Yuejun Luo, Guochao Zhang, Peng Wu, Nan Sun, Jie He · 2021 · Clinical and Translational Medicine
37. Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
    Michael Kuske, Maximilian Haist, Thomas Jung, Stephan Grabbe, Matthias Bros · 2022 · Cancers
38. Immunomodulatory effects of CDK4/6 inhibitors
    Shumeng Zhang, Qiaomai Xu, Wenjia Sun, Jianya Zhou, Jianying Zhou · 2023 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
39. Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer
    Eleonora Ghisoni, Fabrizio Benedetti, Aspram Minasyan, Mathieu Desbuisson, Paula Cunnea, Alizée J Grimm, Noémie Fahr, Charlotte Capt, Nicolas Rayroux, Flavia De Carlo et al. · 2025 · Cancer Cell
40. Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy
    Marica Eoli, Cristina Corbetta, Elena Anghileri, Natalia Di Ianni, Micaela Milani, Valeria Cuccarini, Silvia Musio, Rosina Paterra, Simona Frigerio, Sara Nava et al. · 2019 · Neuro-Oncology Advances
41. Cancer Cells Resistance Shaping by Tumor Infiltrating Myeloid Cells
    Marcin Domagala, Chloé Laplagne, Edouard Leveque, Camille Laurent, Jean‐Jacques Fournié, Éric Espinosa, Mary Poupot · 2021 · Cancers
42. Interferon Signaling in Estrogen Receptor–positive Breast Cancer: A Revitalized Topic
    Xiaoyong Fu, Carmine De Angelis, Rachel Schiff · 2021 · Endocrinology
43. Current landscape and perspective of oncolytic viruses and their combination therapies
    Yinghan Su, Changqing Su, Lun–Xiu Qin · 2022 · Translational Oncology
44. Blocked Autophagy is Involved in Layered Double Hydroxide‐Induced Repolarization and Immune Activation in Tumor‐Associated Macrophages
    Guoxin Jing, Linnan Yang, Hong Wang, Jintong Niu, Huichao Wang, Yi Gao, Youyuan Li, Bangguo Wei, Yechang Qian, Shilong Wang · 2023 · Advanced Healthcare Materials
45. CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity
    Ramin Salehi‐Rad, Raymond J. Lim, Yushen Du, Linh My Tran, Rui Li, Stephanie L Ong, Zi Ling Huang, Camelia Dumitras, Tian-hao Zhang, Stacy J. Park et al. · 2023 · Journal for ImmunoTherapy of Cancer
46. Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject ‘cold’ tumors
    Monika Semmrich, Jean-Baptiste Marchand, Laetitia Fend, Matilda Rehn, Christelle Remy, Petra Holmkvist, Nathalie Silvestre, Carolin Svensson, Patricia Kleinpeter, Jules Deforges et al. · 2022 · Journal for ImmunoTherapy of Cancer
47. Noncanonical MAVS signaling restrains dendritic cell–driven antitumor immunity by inhibiting IL-12
    Lingling Wu, Xiaochuan Hong, Chao Xian Yang, Yuanqin Yang, Wenwen Li, Lu Lu, Mei‐Chun Cai, Dongqing Cao, Guanglei Zhuang, Liufu Deng · 2023 · Science Immunology
48. Recombination Monophosphoryl Lipid A-Derived Vacosome for the Development of Preventive Cancer Vaccines
    Ruoyu Cheng, Flavia Fontana, Junyuan Xiao, Zehua Liu, Patrícia Figueiredo, Mohammad‐Ali Shahbazi, Shiqi Wang, Jing Jin, Giulia Torrieri, Jouni J. Hirvonen et al. · 2020 · ACS Applied Materials & Interfaces
49. Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial
    Julia Katharina Schwarze, Gil Awada, Louise Cras, Jens Tijtgat, Ramses G. Forsyth, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet, Bart Neyns · 2020 · Vaccines
50. Applications of Single-Cell Omics to Dissect Tumor Microenvironment
    Tingting Guo, Weimin Li, Xuyu Cai · 2020 · Frontiers in Genetics
51. iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy
    Dominik Brücher, Nicole Kirchhammer, Sheena N. Smith, Jatina Schumacher, Nina Schumacher, Jonas Kolibius, Patrick C. Freitag, Markus Schmid, Fabian Weiss, Corina Keller et al. · 2021 · Molecular Therapy — Methods & Clinical Development
52. Natural Killer Cells and Dendritic Cells: Expanding Clinical Relevance in the Non-Small Cell Lung Cancer (NSCLC) Tumor Microenvironment
    Pankaj Kumar Ahluwalia, Meenakshi Ahluwalia, Ashis Kumar Mondal, Nikhil Sahajpal, Vamsi K Kota, Mumtaz V. Rojiani, Ravindra B Kolhe · 2021 · Cancers
53. Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy
    Andrea Ziblat, Brendan L. Horton, Emily F. Higgs, Ken Hatogai, Anna Martinez, Jason W. Shapiro, Danny EC Kim, Yuanyuan Zha, Randy F. Sweis, Thomas Frank Gajewski · 2024 · Cell Reports
54. Combined Flt3L and CD40 agonism restores dendritic cell–driven T cell immunity in pancreatic cancer
    Graham D. Hogg, Alyssa G. Weinstein, Natalie L. Kingston, Xiuting Liu, Olivia M. Dres, Liang‐I Kang, Varintra E. Lander, Yu‐Lan Kao, Faiz F. Ahmad, Brett L. Knolhoff et al. · 2025 · Science Immunology
55. LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects
    Hsin-Wei Liao, Christopher Garris, Christina Pfirschke, Steffen Rickelt, Sean P. Arlauckas, Marie R. Siwicki, Rainer H. Köhler, Ralph Weissleder, Vibeke Sundvold‐Gjerstad, Baldur Sveinbjørnsson et al. · 2019 · Cell Stress
56. Combinatorial Immunotherapies for Metastatic Colorectal Cancer
    Eline Janssen, Beatriz Subtil, Fàtima de la Jara Ortiz, Henk M.W. Verheul, Daniele V. F. Tauriello · 2020 · Cancers
57. Preclinical platform for long-term evaluation of immuno-oncology drugs using hCD34+ humanized mouse model
    Nahee Park, Kamal Pandey, Sei Kyung Chang, Ah‐Young Kwon, Young Bin Cho, Jin Hur, Nar Bahadur Katuwal, Seung‐Ki Kim, Seung Ah Lee, Gun Woo Son et al. · 2020 · Journal for ImmunoTherapy of Cancer
58. A Double-Edged Sword Role of Cytokines in Prostate Cancer Immunotherapy
    Chenyu Mao, Yongfeng Ding, Nong Xu · 2021 · Frontiers in Oncology
59. Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy
    Chris Y. H. Chiu, J. Judy Chang, Ashanti Dantanarayana, Ajantha E. Solomon, Vanessa A. Evans, Rachel D. Pascoe, Céline Gubser, Lydie Trautmann, Rémi Fromentin, Nicolas Chomont et al. · 2021 · The Journal of Immunology
60. MMP-responsive transformation nanomaterials with IAP antagonist to boost immune checkpoint therapy
    Ting Wang, Zheng He, Cong-Shan Yuan, Zhenwei Deng, Fang Li, Xiguang Chen, Ya Liu · 2022 · Journal of Controlled Release
61. Dendritic cell-based cancer immunotherapy in the era of immune checkpoint inhibitors: From bench to bedside
    Farid Ghorbaninezhad, Zahra Asadzadeh, Javad Masoumi, Ahad Mokhtarzadeh, Tohid Kazemi, Leili Aghebati Maleki, Siamak Sandoghchian Shotorbani, Mahdi Abdoli Shadbad, Amir Baghbanzadeh, Nima Hemmat et al. · 2022 · Life Sciences
62. Efficacy of CD40 Agonists Is Mediated by Distinct cDC Subsets and Subverted by Suppressive Macrophages
    Aleksandar Murgaski, Máté Kiss, Helena Van Damme, Daliya Kancheva, Isaure Vanmeerbeek, Jiri Keirsse, Éva Hadadi, Jan Brughmans, Sana M. Arnouk, Ahmed E.I. Hamouda et al. · 2022 · Cancer Research
63. Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells
    Sandra Gessani, Filippo Belardelli · 2019 · Cancers
64. The Spatial Organization of cDC1 with CD8+ T Cells is Critical for the Response to Immune Checkpoint Inhibitors in Patients with Melanoma
    Élisa Gobbini, Margaux Hubert, Anne‐Claire Doffin, Anaïs Eberhardt, Léo Hermet, Danlin Li, Pierre Duplouye, Sarah Barrin, Justine Berthet, Valentin Benboubker et al. · 2025 · Cancer Immunology Research
65. Epigenetics of Dendritic Cells in Tumor Immunology
    Gerard Godoy‐Tena, Esteban Ballestar · 2022 · Cancers
66. T-cell engaging poly(lactic-co-glycolic acid) nanoparticles as a modular platform to induce a potent cytotoxic immunogenic response against PD-L1 overexpressing cancer
    Ramesh Duwa, Ram Hari Pokhrel, Asmita Banstola, Mahesh Pandit, Prakash Sunder Shrestha, Jee‐Heon Jeong, Jae‐Hoon Chang, Simmyung Yook · 2022 · Biomaterials
67. Preclinical development and clinical studies of targeted JAK/STAT combined Anti-PD-1/PD-L1 therapy
    Miaomiao Chen, Si-Liang Wang · 2024 · International Immunopharmacology
68. Modeling T cell temporal response to cancer immunotherapy rationalizes development of combinatorial treatment protocols
    O. Barboy, A. Bercovich, Han-Jie Li, Y. Eyal-Lubling, Adam Yalin, Yuval Shapir Itai, Kathleen Abadie, M. Zada, Eyal David, Shir Shlomi-Loubaton et al. · 2024 · Nature Cancer
69. Evaluation of cytokines in the tumor microenvironment of lung cancer using bronchoalveolar lavage fluid analysis
    Pascal Bezel, Alan Valaperti, Urs Christian Steiner, Dieter Scholtze, Stephan Wieser, Maya Eisenring, Andrea Widmer, Benedikt Kowalski, Malcolm Kohler, Daniel Franzen · 2021 · Cancer Immunology Immunotherapy
70. In Vivo Click Chemistry Enables Multiplexed Intravital Microscopy
    Jina Ko, Kilean Lucas, Rainer H. Köhler, Elias A. Halabi, Martin Wilkovitsch, Jonathan Carlson, Ralph Weissleder · 2022 · Advanced Science
71. NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets
    Alice Indini, Irene Fiorilla, Luca Ponzone, Enzo Calautti, Valentina Audrito · 2022 · International Journal of Molecular Sciences
72. mRNA vaccination in breast cancer: current progress and future direction
    Xiaoting Jiang, Qiang Liu · 2023 · Journal of Cancer Research and Clinical Oncology
73. Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity
    Laura Fernandez-Rodriguez, Chiara Cianciaruso, Ruben Bill, Marcel P. Trefny, Richard Klar, Nicole Kirchhammer, Mélanie Buchi, Julia Festag, Sven Michel, Rainer H. Köhler et al. · 2023 · Journal for ImmunoTherapy of Cancer
74. Engineering dendritic cell biomimetic membrane as a delivery system for tumor targeted therapy
    Huiyang Liu, Yiming Lu, Jinbao Zong, Bei Zhang, Xiaolu Li, Hongzhao Qi, Tao Yu, Yu Li · 2024 · Journal of Nanobiotechnology
75. Reactivation of dysfunctional dendritic cells by a stress-relieving nanosystem resets anti-tumor immune landscape
    Yichao Lu, Yingying Shi, Zhenyu Luo, Xuemeng Guo, Mengshi Jiang, Xiang Li, Junlei Zhang, Chunqi Zhu, Hang Yin, Bing Qin et al. · 2022 · Nano Today
76. Association of increased B7 protein expression by infiltrating immune cells with progression of gastric carcinogenesis
    Lingchuan Guo, Zhiju Liu, Yun Zhang, Qiuying Quan, Lili Huang, Yunyun Xu, Lei Cao, Xueguang Zhang · 2019 · Medicine
77. Combination CXCR4 and PD-1 Blockade Enhances Intratumoral Dendritic Cell Activation and Immune Responses Against Hepatocellular Carcinoma
    Satoru Morita, Pin‐Ji Lei, Kohei Shigeta, Tomofumi Ando, Tatsuya Kobayashi, Hiroto Kikuchi, Aya Matsui, Peigen Huang, Mikaël J. Pittet, Dan Gabriel Duda · 2024 · Cancer Immunology Research
78. IFN-Alpha-Mediated Differentiation of Dendritic Cells for Cancer Immunotherapy: Advances and Perspectives
    Caterina Lapenta, Lucia Gabriele, Stefano M. Santini · 2020 · Vaccines
79. Design of PD-1-decorated nanocages targeting tumor-draining lymph node for promoting T cell activation
    Gi Beom Kim, Hyo-Dong Sung, Gi‐Hoon Nam, Wonjun Kim, Seohyun Kim, Dayeon Kang, Eun Jung Lee, In-San Kim · 2021 · Journal of Controlled Release
80. A review on the role of gut microbiota in immune checkpoint blockade therapy for cancer
    Esther S. Kim, Hyeok Ahn, Hansoo Park · 2021 · Mammalian Genome
81. Cocktail strategy for ‘cold’ tumors therapy via active recruitment of CD8+ T cells and enhancing their function
    Xiang Li, Lihua Luo, Mengshi Jiang, Chunqi Zhu, Yingying Shi, Junlei Zhang, Bing Qin, Zhenyu Luo, Xuemeng Guo, Yichao Lu et al. · 2021 · Journal of Controlled Release
82. Antigen transfer and its effect on vaccine-induced immune amplification and tolerance
    Yingying Shi, Yichao Lu, Jian You · 2022 · Theranostics
83. Dendritic Cells: The Long and Evolving Road towards Successful Targetability in Cancer
    Enrica Marmonti, Jacqueline Oliva, Cara Haymaker · 2022 · Cells
84. The spatial distribution of immune cell subpopulations in hepatocellular carcinoma
    Pengcheng Wang, Zhiqiang Hu, Shao‐Lai Zhou, Songyang Yu, Li Mao, Sheng Su, Lee Jia, Ning Ren, Xiaowu Huang · 2021 · Cancer Science
85. Therapeutic inhibition of the SRC-kinase HCK facilitates T cell tumor infiltration and improves response to immunotherapy
    Ashleigh R. Poh, Christopher G. Love, David Chisanga, James H. Steer, David Baloyan, Michaël Chopin, Stephen L. Nutt, Jai Rautela, Nicholas D. Huntington, Nima Etemadi et al. · 2022 · Science Advances
86. Dendritic cells Trigger IFN‐γ secretion by NK cells independent of IL‐12 and IL‐18
    Kaveh Abdi, Karen Laky, Mehrnoosh Abshari, Elizabeth M. Hill, Larry M. Lantz, Nevil J. Singh, Eric O. Long · 2022 · European Journal of Immunology
87. XCR1+ DCs are critical for T cell-mediated immunotherapy of chronic viral infections
    Eva Domenjo‐Vila, Valentina Casella, Ryutaro Iwabuchi, Even Fossum, Mireia Pedragosa, Quim Castellví, Paula Cebollada Rica, Tsuneyasu Kaisho, Kazutaka Terahara, Gennady Alekseevich Bocharov et al. · 2023 · Cell Reports
88. The Role and Potential Application of IL-12 in the Immune Regulation of Tuberculosis
    H J Wang, Guiren Ruan, Yuanchun Li, Xiaoqing Liu · 2025 · International Journal of Molecular Sciences
89. Dendritic cells instruct T cell anti-tumor immunity and immunotherapy response
    Zhen Xiao, Jiajia Wang, Jingxing Yang, Feng Guo, Liyuan Zhang, Lianjun Zhang · 2025 · The Innovation Medicine
90. A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis
    Jin Qian, Chenkai Ma, Quin T. Waterbury, Xiaofei Zhi, Christine S. Moon, Ruhong Tu, Hiroki Kobayashi, Feijing Wu, Biyun Zheng, Yi Zeng et al. · 2024 · Cancer Cell
91. Marine Seagrass Extract of Thalassia testudinum Suppresses Colorectal Tumor Growth, Motility and Angiogenesis by Autophagic Stress and Immunogenic Cell Death Pathways
    Ivones Hernández, Idania Rodeiro, Ken Declerck, J. Herrera, Claudina Angela Perez-Novo, Guy Van Camp, Olivier De Wever, Kethia González, Mayrel Labrada, Adriana Carr et al. · 2021 · Marine Drugs
92. Cell differentiation trajectory predicts patient potential immunotherapy response and prognosis in gastric cancer
    Renshen Xiang, Yuping Rong, Yuhang Ge, Wei Song, Jun Ren, Tao Fu · 2021 · Aging
93. IFN-Gamma Expression in the Tumor Microenvironment and CD8-Positive Tumor-Infiltrating Lymphocytes as Prognostic Markers in Urothelial Cancer Patients Receiving Pembrolizumab
    Toru Sakatani, Yuki Kita, Masakazu Fujimoto, Takeshi Sano, Akihiro Hamada, Kenji D. Nakamura, Hideaki Takada, Takayuki Goto, Atsuro Sawada, Shusuke Akamatsu et al. · 2022 · Cancers
94. Chemoimmunological Cascade Cancer Therapy Using Fluorine Assembly Nanomedicine
    Qingyan Zhang, Pengkai Wu, Jicheng Wu, Hao Shou, Xinliang Ming, Shuqi Wang, Ben Wang · 2023 · ACS Nano
95. Sunitinib attenuates reactive MDSCs enhancing anti-tumor immunity in HNSCC
    Jie Liu, Wen‐Ping Lin, Wen Su, Zhi‐Zhong Wu, Qi‐Chao Yang, Shuo Wang, Ting-Guan Sun, Cong‐Fa Huang, Xiaolong Wang, Zhi‐Jun Sun · 2023 · International Immunopharmacology
96. Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients
    Katarina Mirjačić Martinović, Ana M. Vuletić, Nevena Tišma Miletić, Irina Besu, Jelena Milovanović, Suzana Matković, Vladimir Jurišić · 2023 · Translational Oncology
97. Dendritic cells: the yin and yang in disease progression
    Carlos Jiménez‐Cortegana, Francisca Palomares, Gonzalo Álba, Consuelo Santa‐María, Luis de la Cruz‐Merino, Víctor Sánchez‐Margalet, Soledad López-Enríquez · 2024 · Frontiers in Immunology
98. PD ‐1: A critical player and target for immune normalization
    Xuening Liu, Alison Zhao, Su Xiao, Haohao Li, Menghua Li, Wei Guo, Qiuju Han · 2024 · Immunology
99. Orchestrating intratumoral DC-T cell immunity for enhanced tumor control via radiotherapy-activated TLR7/8 prodrugs in mice
    Xiaozhe Yin, Zexuan Ding, Yu Li, Xuhao Zhang, Yu Gao, Yiyan Li, Zhibo Liu, Yang‐Xin Fu · 2025 · Nature Communications
100. Senescent immune cells in the tumor microenvironment: emerging insights into cancer immunotherapy resistance
     Duolun Gao, Peiyan Kan, Yanjie He, Siyu Sun, Lei Tang, Fan Yang · 2025 · Frontiers in Immunology